REFERENCES
- Louie M, Hogan C, Di Mascio M, et al. Determining the rela-tive efficacy of highly active antiretroviral therapy. J Infect Dis. 2003;187:896–900.
- Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and long term efficacy. Lan-cet. 2001;358:1760–1765.
- Ruane PJ, Parenti DM, Margolis D, et al. Compact quadru-ple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lami-vudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment naive HIV infected adults. HIV Clin Trials. 2003;4(4):231–243.
- De Truchis P, Force G, Welker Y, et al. Efficacy and safety of a quadruple combination Combivir + abacavir + efavi-renz regimen in antiretroviral treatment naive HIV-1 infected adults; La Francilienne. J Acquir Immune Defic Syndr 2002;31:178–182.
- Mathez D, Schinazi RF, Leibowitch J. Infectious amplifi-cation of wild-type human immunodeficiency virus from patients lymphocytes and modulation by reverse tran-scriptase inhibitors in vitro. Antimicrob Agents Chemother 1993;37:2206–2211.
- De Wit S, Johnson M, Gazzard B, et al. Randomised com-parison of maintenance therapy with Trizivir (TZV) +Efavi-renz (RFV) vs TZV in naive HIV-1 infected subjects: Time Study. Presented at: Seventh International Congress on Drug Therapy and HIV Infection; November 14–18, 2004; Glasgow. Abstract P.I.2.4.
- Markowitz M, Hill-Zabala C, Lang J, et al. ESS40013 Study: induction with abacavir/lamivudine/zidovudine plus efavi-renz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-na-ive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:257–264.
- Reynes J, Ragnaud JM, Gallais H, et al. An open label study to evaluate long term (96 weeks) safety and efficacy of switch to Trizivir after first line quadruple induction ther-apy: AZF3004 -Trisud. In: Program and abstracts of the Ninth European AIDS Conference (EACS); October 25–29, 2003. Abstract 7.5/3
- Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivu-dine and zidovudine in Human Immunodeficiency Virus infection. J Infect Dis. 2002;185:1251–1260.
- Katlama C, Fenske S, Gazzard B, et al. Trizal Study: switch-ing from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med. 2003;4:79–85.
- Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus con-tinued Fl-based HAART in HIV-1 infected patients with un-detectable plasma HIV-1 RNA. AIDS. 200115: 1517–1526.
- Saimot AG, Landman R, Damond D, et al. Ritonavir, stavu-dine (d4T), didanosine (ddl) as a triple therapy in antiretro-viral-naive patients. Antiviral Ther 1997;2:129–131.
- Leibowitch J, Mathez D, Elissalt M, et al. The five-to-one trial: 5 antiretrovirals combined during 6 months in treat-ment-naive HIV-1 infected patients. Presented at: 12th World AIDS Conference; 1998; Geneva.
- Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the Mitox Extension Study. AIDS. 2004;18:1029–1036.